SBIR-STTR Award

Novel 3-D Printed Implant for Improved Hemodialysis Access
Award last edited on: 9/21/2022

Sponsored Program
SBIR
Awarding Agency
NIH : NHLBI
Total Award Amount
$2,153,319
Award Phase
2
Solicitation Topic Code
837
Principal Investigator
Ashok Gowda

Company Information

BioTex Inc (AKA: Visualase)

8058 El Rio Drive
Houston, TX 77054
   (713) 741-0111
   ashok@biotexmedical.com
   www.biotexmedical.com
Location: Single
Congr. District: 09
County: Harris

Phase I

Contract Number: 1R44HL154933-01
Start Date: 7/24/2020    Completed: 6/30/2022
Phase I year
2020
Phase I Amount
$795,029
The overall goal of this Direct to Phase II SBIR proposal is to develop the Ark, a novel device for providing improved access, protection, and functionality during placement of hemodialysis needles. In the US alone, over 700,000 patients receive hemodialysis treatment, and creation of an arteriovenous fistula (AVF) and access vein is the preferred access point for dialysis needles. Most access veins suffer from the following shortcomings: long waiting periods to mature; challenging to access; prone to damage by needle penetration through the vessel; and limited useful life, failing largely because of both excessive and poor punctures. As a result, many dialysis patients do not receive the treatment required for continued quality of life. The Ark is designed to remediate the limitations of the current practice and aid long-term use of access veins. The Ark is intended for surgical implantation around the access vein, ideally at the time of AVF creation. The infrastructure promotes ingrowth of surrounding soft tissues reinforcing the strength of the vein, while providing an opening for easy needle access and a back wall for vessel protection from inadvertent penetration. The implant provides a palpable structure beneath the skin, promoting more accurate needle puncture, improving both caregiver efficacy and patient comfort. Initial prototypes of the Ark have gone through preliminary benchtop and animal studies demonstrating feasibility and significant promise. Continued efforts will build on these results to optimize the design, perform cannulation studies in a relevant AVF animal model, complete required design controls and validation activities, and perform a chronic GLP study, supporting a planned submission for FDA Clearance. We expect the end result of this effort will greatly facilitate the move toward home-based dialysis, resulting in significant impact on patient health and health care cost savings.

Public Health Relevance Statement:
Project Narrative Patients with chronic kidney disease must undergo hemodialysis a minimum of three times per week for up to four hours per treatment, but more frequent dialysis results in a significant improvement in their quality of life. Increasing the treatment frequency comes with its own set of complications, including: increased risk of infiltration, weakening of the vessel wall at the access site, and low blood flow from collapsing vessels, among other factors leading to failure of the access vein. The Ark is intended to improve access, eliminate the need for excessive punctures, and prevent penetration of vessel side and back walls, ultimately lengthening the useful life of the access vein and restoring the ongoing quality of life of long-term dialysis patients.

Project Terms:
3D Print; Anatomy; animal data; Animal Model; Animals; arm; Arteriovenous fistula; Back; base; Blood; Blood flow; Blood Vessels; Caliber; Cannulations; capsule; Caregivers; Characteristics; Chronic; Chronic Kidney Failure; Clinical; Consult; Cost Savings; design; Device Designs; Devices; Dialysis patients; Dialysis procedure; Engineering; Evaluation; exoskeleton; Extravasation; Failure; first-in-human; Frequencies; Goals; Goat; Health Care Costs; Healthcare; Hemodialysis; Histologic; Home environment; Hour; Human; Implant; implantation; Improve Access; improved; Industrialization; Infiltration; Infrastructure; Institutes; Life; Limb structure; Measures; Mechanics; Medical; meetings; member; metallicity; Modeling; Needles; novel; Operative Surgical Procedures; Palpable; Palpation; Patients; Penetration; Phase; Physicians; preclinical study; prevent; product development; Protocols documentation; prototype; Puncture procedure; Quality of life; Regulatory Pathway; response; Risk; Safety; Side; Silicones; Site; Skin; Small Business Innovation Research Grant; soft tissue; Structure; success; Testing; Texas; Time; Tissue Model; Tissues; Titanium; Training; Ultrasonography; Universities; Update; Validation; Variant; Veins; verification and validation; Work

Phase II

Contract Number: 5R44HL154933-02
Start Date: 7/24/2020    Completed: 6/30/2023
Phase II year
2021
Phase II Amount
$1,358,290
The overall goal of this Direct to Phase II SBIR proposal is to develop the Ark, a novel device forproviding improved access, protection, and functionality during placement of hemodialysis needles. Inthe US alone, over 700,000 patients receive hemodialysis treatment, and creation of an arteriovenousfistula (AVF) and access vein is the preferred access point for dialysis needles. Most access veins sufferfrom the following shortcomings: long waiting periods to mature; challenging to access; prone to damageby needle penetration through the vessel; and limited useful life, failing largely because of both excessiveand poor punctures. As a result, many dialysis patients do not receive the treatment required forcontinued quality of life. The Ark is designed to remediate the limitations of the current practice and aid long-term use ofaccess veins. The Ark is intended for surgical implantation around the access vein, ideally at the time ofAVF creation. The infrastructure promotes ingrowth of surrounding soft tissues reinforcing the strengthof the vein, while providing an opening for easy needle access and a back wall for vessel protectionfrom inadvertent penetration. The implant provides a palpable structure beneath the skin, promotingmore accurate needle puncture, improving both caregiver efficacy and patient comfort. Initial prototypesof the Ark have gone through preliminary benchtop and animal studies demonstrating feasibility andsignificant promise. Continued efforts will build on these results to optimize the design, performcannulation studies in a relevant AVF animal model, complete required design controls and validationactivities, and perform a chronic GLP study, supporting a planned submission for FDA Clearance. Weexpect the end result of this effort will greatly facilitate the move toward home-based dialysis, resultingin significant impact on patient health and health care cost savings.

Public Health Relevance Statement:
Project Narrative Patients with chronic kidney disease must undergo hemodialysis a minimum of three times per week for up to four hours per treatment, but more frequent dialysis results in a significant improvement in their quality of life. Increasing the treatment frequency comes with its own set of complications, including: increased risk of infiltration, weakening of the vessel wall at the access site, and low blood flow from collapsing vessels, among other factors leading to failure of the access vein. The Ark is intended to improve access, eliminate the need for excessive punctures, and prevent penetration of vessel side and back walls, ultimately lengthening the useful life of the access vein and restoring the ongoing quality of life of long-term dialysis patients.

Project Terms:
© Copyright 1983-2024  |  Innovation Development Institute, LLC   |  Swampscott, MA  |  All Rights Reserved.